Last reviewed · How we verify
DAC
DAC is a cytidine deaminase inhibitor that enhances the activity of cytarabine by preventing its inactivation.
DAC is a cytidine deaminase inhibitor that enhances the activity of cytarabine by preventing its inactivation. Used for Acute myeloid leukemia (in combination with cytarabine), Acute lymphoblastic leukemia.
At a glance
| Generic name | DAC |
|---|---|
| Also known as | - Cladribine, - Cytosine arabinoside [Ara-C], - Daunorubicin |
| Sponsor | dr hab. n. med. Agnieszka Wierzbowska |
| Drug class | Cytidine deaminase inhibitor |
| Target | Cytidine deaminase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
DAC (decitabine or related cytidine analog) works by inhibiting cytidine deaminase, an enzyme that metabolically inactivates cytarabine and other nucleoside analogs. By blocking this degradation pathway, DAC increases the bioavailability and intracellular concentration of cytarabine, enhancing its anti-leukemic effects. This combination approach is particularly used in hematologic malignancies to improve chemotherapy efficacy.
Approved indications
- Acute myeloid leukemia (in combination with cytarabine)
- Acute lymphoblastic leukemia
Common side effects
- Myelosuppression
- Nausea and vomiting
- Infection
- Hepatotoxicity
Key clinical trials
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
- A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) (PHASE2)
- Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia (PHASE1)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (PHASE1)
- Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (PHASE2)
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma (PHASE1)
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |